Featured Research

from universities, journals, and other organizations

HIV Drug Leaves Key Part Of Immune System Vulnerable

Date:
November 30, 2000
Source:
Ohio State University
Summary:
A drug that helps to slow the progression of HIV - the virus that causes AIDS - does not seem to prevent virus-related damage to an organ critical to the development of the immune system. This organ, called the thymus, is especially important early in life when the human immune system is developing.

COLUMBUS, Ohio - A drug that helps to slow the progression of HIV - the virus that causes AIDS - does not seem to prevent virus-related damage to an organ critical to the development of the immune system.

This organ, called the thymus, is especially important early in life when the human immune system is developing.

Infants who contract the virus from their mothers are particularly prone to developing immune system problems because of the damage HIV ultimately causes to the thymus.

Pregnant mothers who are HIV-positive are often given AZT, a drug that helps prevent the fetus from contracting the virus. In children and adults with HIV, AZT helps control and even reduces the proliferation of the virus in the blood.

Researchers at Ohio State University tested the effect of the drug AZT on the thymuses of young cats infected with FIV -- a virus which behaves similar to HIV and one that causes an AIDS-like disease in cats. They found that although AZT helped control and even reduce the amount of FIV in the blood and inthe thymus, the virus still was able to cause significant physical damage to the thymus.

"This lack of protection surprised us," said Larry Mathes, a study co-author and a professor of veterinary biosciences at Ohio State. "It suggests that antiviral therapy in infants may need to be combined with other treatments - such as other drugs - in order to restore thymic function."

The study appears in a recent issue of the journal Antimicrobial Agents and Chemotherapy.

The researchers already knew that AZT reduces the levels of FIV and HIV in blood outside of the thymus. (AZT is also called zidovudine (ZDV) or Retrovir.) Cats were placed into one of four groups: in the first, cats were infected with FIV and treated with AZT. In a second, the animals were infected with FIV and treated with placebo. The third contained uninfected, AZT-treated cats and in the fourth, the cats remained uninfected and received only a placebo instead of AZT.

The cats received daily doses of AZT for 12 weeks. Treatment began two days before the cats were infected with the virus, so researchers could compare the levels of certain immune system cells - T cells - in the infected and uninfected groups. The virus attacks and kills T cells, which mature in the thymus.

Levels of virus present in the blood samples were determined at four, eight and 12 weeks after the initial infection. The experiments ended after 12 weeks and the researchers examined the animal's thymus glands for signs of infection.

Animals receiving the AZT treatment showed significantly reduced (by 75 to 85 percent) levels of virus in the blood and also in the thymus (by about 74 percent) when compared to animals which were infected but not treated. Yet the FIV had ultimately caused similar physical damage and inflammation to the thymuses of the cats in both of the infected groups.

Inflammation is a typical immune response to a virus or an injury - it's part of the healing process. The immune system tried to get rid of the virus in the thymus, so it launched an attack, which caused the inflammation. But reducing the virus level didn't cause the inflammation to subside. "We're not sure why it didn't," Mathes said.

"It would make sense that a decrease in virus levels would mean that the inflammation would subside and that the thymus would improve," he said. "Since that didn't happen, we assumed that it was the immune response that ended up damaging the thymus.

"Our long-term goal is to develop a therapeutic strategy to protect the thymus," Mathes said. "We want to find how we can protect it."

The research was supported by grants from the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. The study was co-authored by Kathleen Hayes, of the department of veterinary biosciences at Ohio State, and former Ohio State graduate research assistants Andrew Phipps, currently at Battelle Memorial Institute, and Sabine Francke, currently at Novartis Pharmaceuticals.


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "HIV Drug Leaves Key Part Of Immune System Vulnerable." ScienceDaily. ScienceDaily, 30 November 2000. <www.sciencedaily.com/releases/2000/11/001129074858.htm>.
Ohio State University. (2000, November 30). HIV Drug Leaves Key Part Of Immune System Vulnerable. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2000/11/001129074858.htm
Ohio State University. "HIV Drug Leaves Key Part Of Immune System Vulnerable." ScienceDaily. www.sciencedaily.com/releases/2000/11/001129074858.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins